# Obstructive Sleep Apnea in the Elderly

Sanjay R. Patel MD, MS

Professor of Medicine & Epidemiology, University of Pittsburgh

Director, Comprehensive Sleep Disorders Clinic UPMC Presbyterian

I have received grant funding from Bayer Pharmaceuticals, Philips Respironics and Respicardia.


#### Obstructive sleep apnea

Syndrome characterized by repetitive episodes of partial or complete upper airway obstruction during sleep, associated with snoring, sleep fragmentation, and intermittent hypoxemia.






# **Obstructive apnea**




#### **Definitions**

- Apnea: No airflow for 10 seconds or longer.
- Hypopnea: A decrement in airflow lasting longer than 10 seconds. Commonly requires a fall in oxygen saturation and/or arousal.
- Apnea Hypopnea Index (AHI): Total number of apneas and hypopneas divided by hours asleep
  - AHI < 5 normal
  - AHI 5-15 mild OSA
  - AHI 15-30 moderate OSA
  - AHI > 30 severe OSA




# **OSA risk factors in older adults**


- Increasing age
- Obesity (importance wanes with age)
- Male gender (less important after menopause)
- Excess soft tissue in airway (Mallampati score)
- Retrognathia
- Alcohol use





# **OSA signs and symptoms**

- Loud snoring (less prevalent in older age)
- Witnessed apnea, choking/gasping arousals
- Daytime sleepiness, fatigue, poor concentration
- Nocturnal awakenings, nocturia
- Depressed mood
- Hypertension, diabetes, cardiovascular disease









# **PCP screening for OSA**

- Study of 5 Practice Based Research Networks across the country.
- 23% of PCPs routinely screen for OSA all using review of systems.
- Prevalence of OSA diagnosis was 8.9%

Patients without OSA diagnosis	Age 30-64 (n=1124)	Age ≥ 65 (n=630)	
Loud snoring	57%	46%	
Daytime tiredness	65%	49%	
Falling asleep driving	17%	10%	
Discussed symptoms with PCP	22%	18%	

Mold JW et al, JABFM 2011; 24:138-45

# **Reasons to treat OSA**

#### • Proven reasons:

Improve symptoms (snoring, sleepiness, vitality, nighttime awakenings)


# • Theoretical reasons:

- Reduce CVD risk (stroke, heart failure, CAD, Afib, DM, mortality)
- Reduce risk of cognitive decline/dementia

# Continuous Positive Airway Pressure





# **CPAP** improves sleepiness



Mean improvement in Epworth score of 2.9.

Patel SR et al, Arch Int Med 2003; 163:565-71







# **CPAP** and Cognition


- 6-month RCT of 1,105 OSA patients to CPAP or sham.
- Mean AHI 40
- Significant improvement in sleepiness.
- No improvement in attention, psychomotor function, learning, memory, executive function or frontal lobe function.

Kushida CA et al, Sleep 2012; 35: 1593-602







# How to diagnose and initiate OSA treatment?





# Shortfalls of traditional pathway

- Limited by number of sleep beds and techs.
  - Long waiting times
- Inconvenient to many patients.
  - Those with caregiver responsibilities
  - Those with transportation issues at night
  - Those uncomfortable with sleeping in front of strangers









# **Cost effectiveness of home testing**


- CPAP acceptance: 87% in lab vs. 84% in home
- Patient preference:
  76% home testing vs. 24% lab testing
- Costs per patient:
  \$1001 in lab vs. \$744 in home
  €736 in lab vs. €320 in home
- No difference in traffic accidents, hospitalizations, or CV events.

Skomro RP et al, Chest 2010; 138:257-63; Rosen CL et al, Sleep 2012; 35:757-67; Corral J et al, AJRCCM 2017; 196:1181-90

# **Study limitations**

- All studies exclude those at high risk for alternative forms of sleep-disordered breathing (CHF, COPD, opiate use, etc).
- Role of home testing in these patients remains unclear.

# What if CPAP is not tolerated?



# Oxygen vs. CPAP vs. no treatment

 Randomized trial of 281 patients found no effect of oxygen on BP or other cardiovascular measures.

Variable	CPAP (N=90)	NSO (N = 94)	HLSE (N = 97)	CPAP vs. HLSE	NSO vs. HLSE	CPAP vs. NSO
24-Hr mean arterial blood pressure						
Baseline	89.5±8.6	88.6±10.0	87.7±9.3			
12 Wk	87.8±8.1	90.2±11.1	89.0±11.2	-2.4 (P=0.04)	0.4 (P=0.71)	-2.8 (P=0.02)
24-Hr mean systolic blood pressure						
Baseline	124.7±13.5	125.3±16.9	123.6±14.3			
12 Wk	123.4±12.8	126.9±16.5	124.7±16.4	-1.9 (P=0.25)	1.2 (P=0.45)	-3.1 (P=0.06)
24-Hr mean diastolic blood pressure						
Baseline	72.0±7.7	70.8±8.3	69.6±8.6			
12 Wk	69.8±7.5	71.7±9.8	70.9±10.1	-2.8 (P=0.005)	-0.1 (P=0.95)	-2.8 (P=0.006

Gottlieb DJ et al, NEJM 2014; 370:2276-85

# Mandibular advancement devices



- Pull mandible forward resulting in dilation of the upper airway
- ~55% success rate in normalizing AHI
- More preferable than CPAP to patients
- Adherence is greater than CPAP


#### RCT of CPAP vs. MAD

- Randomized 126 patients in cross-over fashion to CPAP vs. MAD
- Residual AHI better with CPAP (4.5 vs. 11.1)
- Adherence better with MAD (6.5 h vs. 5.2 h)
- Similar effect on Epworth (7.5 CPAP vs. 7.2 MAD)
- Quality of life better with MAD

Phillips CL et al, AJRCCM 2013; 187: 879-87

# **MAD Details**

- Prerequisites
  - Teeth (at least 4 teeth per quadrant)
  - Ability to move mandible forward
  - Better outcomes with sleep specialist dentists
- Side Effects
  - TMJ pain
  - Tooth pain/movement



# **Medicare bureaucracy**

- OSA therapy will only be covered if a face to face visit documenting reason OSA is suspected occurs <u>PRIOR</u> to sleep study
- CPAP initially covered for 3 months, based on:
  - Sleep study showing AHI4% ≥ 5 (past 12 months if new order)
- CPAP covered beyond 3 months, based on:
  - Face to face encounter documenting benefit
  - Adherence (≥4 hrs on 70% of nights in a consecutive 30-day period)
- New style of CPAP mask covered, based on:
  - Face to face encounter documenting benefit in past 12 months